W e have come a long way since the identification of the first human tumor antigen recognized by autologous CTL. This report provides a brief appraisal of these antigens and their potential for cancer immunotherapy. Our comments will be restricted to nonviral antigens.
No takes yet. Share an insight, caveat, or question.
Boon et al. (1996) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: